loperamide has been researched along with Colorectal Neoplasms in 8 studies
Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.
loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-seven colorectal cancer patients with grade 1-4 diarrhea (NCICTC) caused by chemotherapy with 5-FU-containing regimens, received oral loperamide at the initial dose of 4 mg followed by 4 mg every 8 h (total dose 16 mg/24 h)." | 9.09 | High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients. ( Agostinelli, R; Amadori, D; Bichisao, E; Cascinu, S; Catalano, G; Catalano, V; Giordani, P; Luppi, G; Sansoni, E; Silingardi, V, 2000) |
| " The incidence of severe diarrhea is reduced by using a starting dose of irinotecan 125 mg/m2 and by initiating loperamide at the earliest signs of diarrhea." | 9.08 | Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. ( Burris, HA; Eckardt, JR; Eckhardt, SG; Elfring, GL; Hilsenbeck, SG; Kuhn, JG; Nelson, J; Rinaldi, DA; Rodriguez, GI; Rothenberg, ML; Schaaf, LJ; Smith, LS; Thurman, AM; Von Hoff, DD; Weiss, GR, 1996) |
| " The first cohort of 14 consecutive patients explored for the mechanism of diarrhea received acetorphan (a new enkephalinase inhibitor) 100 mg three times daily; the second 14-patient cohort received, in addition to acetorphan, loperamide 4 mg three times daily." | 9.08 | Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. ( Bastian, G; Bonnay, M; Cote, C; Cvitkovic, E; Hagipantelli, R; Herait, P; Mahjoubi, M; Mignard, D; Misset, JL; Saliba, F; Vassal, G, 1998) |
| "Eighty patients with colorectal cancer were randomized within 2 weeks after surgery to receive either modified BSS or Loperamide combined with the respective dummy." | 5.69 | Effects of Modified Baizhu Shaoyao San on Postoperative Diarrhea in Colorectal Cancer Patients: A Single-Blind, Randomized Controlled Trial. ( Fei, M; Luo, M; Wu, Y; Zhang, J; Zhang, L; Zhu, C, 2023) |
| "Patients with colorectal cancer starting adjuvant or first-line treatment with a chemotherapy combination containing fluorouracil, capecitabine, and/or irinotecan were randomly assigned to receive octreotide LAR 30 mg intramuscularly every 4 weeks (experimental arm) or the physician's treatment of choice in case of diarrhea (control arm)." | 5.19 | Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial. ( Andrade, AC; Barrios, CH; Chinen, RN; Correa, M; Coutinho, AK; del Giglio, A; Dutra, C; Forones, NM; Hoff, PM; Passos, VQ; Portella, Mdo S; Saragiotto, DF; van Eyll, B, 2014) |
| "Thirty-seven colorectal cancer patients with grade 1-4 diarrhea (NCICTC) caused by chemotherapy with 5-FU-containing regimens, received oral loperamide at the initial dose of 4 mg followed by 4 mg every 8 h (total dose 16 mg/24 h)." | 5.09 | High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients. ( Agostinelli, R; Amadori, D; Bichisao, E; Cascinu, S; Catalano, G; Catalano, V; Giordani, P; Luppi, G; Sansoni, E; Silingardi, V, 2000) |
| " The incidence of severe diarrhea is reduced by using a starting dose of irinotecan 125 mg/m2 and by initiating loperamide at the earliest signs of diarrhea." | 5.08 | Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. ( Burris, HA; Eckardt, JR; Eckhardt, SG; Elfring, GL; Hilsenbeck, SG; Kuhn, JG; Nelson, J; Rinaldi, DA; Rodriguez, GI; Rothenberg, ML; Schaaf, LJ; Smith, LS; Thurman, AM; Von Hoff, DD; Weiss, GR, 1996) |
| " The first cohort of 14 consecutive patients explored for the mechanism of diarrhea received acetorphan (a new enkephalinase inhibitor) 100 mg three times daily; the second 14-patient cohort received, in addition to acetorphan, loperamide 4 mg three times daily." | 5.08 | Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. ( Bastian, G; Bonnay, M; Cote, C; Cvitkovic, E; Hagipantelli, R; Herait, P; Mahjoubi, M; Mignard, D; Misset, JL; Saliba, F; Vassal, G, 1998) |
| "A Phase I study was performed to determine the maximum tolerated dose (MTD), toxicities, and pharmacokinetic profile of irinotecan (CPT-11) and its active metabolites when given on a once-every-3-week schedule." | 2.69 | Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. ( Adjei, AA; Alberts, SA; Burch, PA; Elfring, G; Erlichman, C; Goldberg, RM; Miller, LL; Pitot, HC; Reid, JM; Rubin, J; Schaaf, LJ; Skaff, PA; Sloan, JA, 2000) |
| "Irinotecan is a selective inhibitor of topoisomerase I, an enzyme part of the replication and transcription system of DNA." | 2.42 | New approaches to prevent intestinal toxicity of irinotecan-based regimens. ( Alimonti, A; Cognetti, F; Di Palma, M; Ferretti, G; Gelibter, A; Pavese, I; Rasio, D; Satta, F; Vecchione, A, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Fei, M | 1 |
| Zhang, J | 1 |
| Zhu, C | 1 |
| Luo, M | 1 |
| Zhang, L | 1 |
| Wu, Y | 1 |
| Major, GAD | 1 |
| Gunn, D | 1 |
| Hoff, PM | 1 |
| Saragiotto, DF | 1 |
| Barrios, CH | 1 |
| del Giglio, A | 1 |
| Coutinho, AK | 1 |
| Andrade, AC | 1 |
| Dutra, C | 1 |
| Forones, NM | 1 |
| Correa, M | 1 |
| Portella, Mdo S | 1 |
| Passos, VQ | 1 |
| Chinen, RN | 1 |
| van Eyll, B | 1 |
| Alimonti, A | 1 |
| Gelibter, A | 1 |
| Pavese, I | 1 |
| Satta, F | 1 |
| Cognetti, F | 1 |
| Ferretti, G | 1 |
| Rasio, D | 1 |
| Vecchione, A | 1 |
| Di Palma, M | 1 |
| Rothenberg, ML | 1 |
| Eckardt, JR | 1 |
| Kuhn, JG | 1 |
| Burris, HA | 1 |
| Nelson, J | 1 |
| Hilsenbeck, SG | 1 |
| Rodriguez, GI | 1 |
| Thurman, AM | 1 |
| Smith, LS | 1 |
| Eckhardt, SG | 1 |
| Weiss, GR | 1 |
| Elfring, GL | 1 |
| Rinaldi, DA | 1 |
| Schaaf, LJ | 2 |
| Von Hoff, DD | 1 |
| Saliba, F | 1 |
| Hagipantelli, R | 1 |
| Misset, JL | 1 |
| Bastian, G | 1 |
| Vassal, G | 1 |
| Bonnay, M | 1 |
| Herait, P | 1 |
| Cote, C | 1 |
| Mahjoubi, M | 1 |
| Mignard, D | 1 |
| Cvitkovic, E | 1 |
| Cascinu, S | 1 |
| Bichisao, E | 1 |
| Amadori, D | 1 |
| Silingardi, V | 1 |
| Giordani, P | 1 |
| Sansoni, E | 1 |
| Luppi, G | 1 |
| Catalano, V | 1 |
| Agostinelli, R | 1 |
| Catalano, G | 1 |
| Pitot, HC | 1 |
| Goldberg, RM | 1 |
| Reid, JM | 1 |
| Sloan, JA | 1 |
| Skaff, PA | 1 |
| Erlichman, C | 1 |
| Rubin, J | 1 |
| Burch, PA | 1 |
| Adjei, AA | 1 |
| Alberts, SA | 1 |
| Elfring, G | 1 |
| Miller, LL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| LARCID: Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea[NCT00582426] | Phase 3 | 139 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Quality of life (QoL) is evaluated using FACIT-D scale. FACIT-D is composed of 38 items, whose responses range from 0 to 4. The total FACIT-D score may range from 0 to 152. The 38 items compose five subscales, each evaluating a different component of the (QOL). For calculating the subscale score, some items are computed in a reverse fashion, so that higher FACIT-D scores indicate a better (QoL). Descriptive statistics (mean, standard deviation, median, minimum and maximum) are used to summarize FACIT-D scores (total and subscales) by study group at each time point. (NCT00582426)
Timeframe: Baseline to Day 168
| Intervention | Units on a scale (Mean) |
|---|---|
| Octreotide Long Acting Release | 0.5 |
| Standard Treatment | 3.4 |
Number of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis. (NCT00582426)
Timeframe: 6 months overall
| Intervention | Episodes/patients/day (Mean) |
|---|---|
| Octreotide Long Acting Release | 21.6 |
| Standard Treatment | 20.4 |
The percentage of patients developing diarrhea (incidence of grade 1 to 4) during treatment, considering only the worst grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 0=None, 1 = Increase of <4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence; or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse. (NCT00582426)
Timeframe: 6 month overall
| Intervention | Percentage of Participants (Number) |
|---|---|
| Octreotide Long Acting Release | 76.1 |
| Standard Treatment | 78.9 |
For patient, chemotherapy dose reduction due to diarrhea as counted each time it occurred. Chemotherapy dose reduction because of other adverse events related to chemotherapy was not considered. (NCT00582426)
Timeframe: 6 months overall
| Intervention | Percentage of participants (Number) |
|---|---|
| Octreotide Long Acting Release | 26.9 |
| Standard Treatment | 11.3 |
(NCT00582426)
Timeframe: 6 months overall
| Intervention | Percentage of Participants (Number) |
|---|---|
| Octreotide Long Acting Release | 4.5 |
| Standard Treatment | 7.0 |
(NCT00582426)
Timeframe: 6 months overall
| Intervention | Percentage of Participants (Number) |
|---|---|
| Octreotide Long Acting Release | 1.5 |
| Standard Treatment | 1.4 |
(NCT00582426)
Timeframe: 6 months overall
| Intervention | Percentage of patients (Number) |
|---|---|
| Octreotide Long Acting Release | 6 |
| Standard Treatment | 4.2 |
Mean number of episodes of diarrhea is evaluated by patient diaries recorded by cycle. (cycle 1 to cycle 7.) (NCT00582426)
Timeframe: at each cycle (28 days per cycle)
| Intervention | Episodes/patient/cycle (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 (n=20, 18) | Cycle 2 (n=36,38) | Cycle 3 (n=33,39) | Cycle 4 (n=24, 27) | Cycle 5 (n=20,29) | Cycle 6 (n=22, 22) | Cycle 7 (n= 16, 20) | |
| Octreotide Long Acting Release | 2.6 | 8.2 | 6.9 | 8.6 | 8.1 | 6.1 | 4.8 |
| Standard Treatment | 2.2 | 5.9 | 6.7 | 7.1 | 7 | 5.8 | 6.6 |
Grade (severity)of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis by considering only worse grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 1 = Increase of <4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence;or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse. (NCT00582426)
Timeframe: 6 months overall
| Intervention | Percentage of Episodes (Number) | |||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Octreotide Long Acting Release | 65.4 | 23.3 | 11.3 | 0 |
| Standard Treatment | 66.9 | 27.2 | 5.9 | 0 |
Lesions that can be accurately measured in at least one dimension (longest diameter (LD) to be recorded) as > 20 mm with conventional techniques (CT, MRI) or as > 10 mm with spiral CT scan. All measurable lesions up to maximum of 5 lesions per organ and 10 lesions in total representative of all involved organs should be identified as target lesions and recorded and measured at baseline. Complete Response is defined as Disappearance of all target lesions. Partial Response is defined at least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD. (NCT00582426)
Timeframe: Day 56, Day 84, Day 112, Day 140, Day 168
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Day 56 (N=11,2) | Day 84 (N=5,3) | Day 112 (N=1,1) | Day 140 (N=9,1) | Day 168 (N=2,1) | |
| Octreotide Long Acting Release | 45.5 | 60.0 | 100 | 44.4 | 100 |
| Standard Treatment | 0.0 | 100 | 0.0 | 100 | 100 |
Grade (severity) of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis by considering only worse grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 0 = None, 1 = Increase of <4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence; or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse. (NCT00582426)
Timeframe: 6 months overall
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Octreotide Long Acting Release | 41.2 | 25.5 | 33.3 | 0 |
| Standard Treatment | 26.8 | 51.8 | 21.4 | 0 |
2 reviews available for loperamide and Colorectal Neoplasms
| Article | Year |
|---|---|
Chronic diarrhoea in adults: what not to miss.
Topics: Adenocarcinoma; Adenoma; Antidiarrheals; Bile Acids and Salts; Celiac Disease; Chronic Disease; Colo | 2019 |
New approaches to prevent intestinal toxicity of irinotecan-based regimens.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2004 |
6 trials available for loperamide and Colorectal Neoplasms
| Article | Year |
|---|---|
Effects of Modified Baizhu Shaoyao San on Postoperative Diarrhea in Colorectal Cancer Patients: A Single-Blind, Randomized Controlled Trial.
Topics: Colorectal Neoplasms; Diarrhea; Gastrins; Gastrointestinal Diseases; Humans; Loperamide; Motilin; Si | 2023 |
Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2014 |
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
Topics: Adenocarcinoma; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasm | 1996 |
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; | 1998 |
High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients.
Topics: Administration, Oral; Adult; Aged; Antidiarrheals; Antimetabolites, Antineoplastic; Antineoplastic C | 2000 |
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
Topics: Adjuvants, Anesthesia; Adult; Aged; Aged, 80 and over; Antidiarrheals; Antiemetics; Antineoplastic A | 2000 |